These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 16862572)

  • 1. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia.
    Francis S; Karanth M; Pratt G; Starczynski J; Hooper L; Fegan C; Pepper C; Valcarcel D; Milligan DW; Delgado J
    Cancer; 2006 Sep; 107(5):1023-33. PubMed ID: 16862572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
    N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
    Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
    Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
    Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
    Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
    Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
    N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
    Kern W; Dicker F; Schnittger S; Haferlach C; Haferlach T
    Cytometry B Clin Cytom; 2009 Nov; 76(6):385-93. PubMed ID: 19479984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.
    Terrin L; Trentin L; Degan M; Corradini I; Bertorelle R; Carli P; Maschio N; Bo MD; Noventa F; Gattei V; Semenzato G; De Rossi A
    Leukemia; 2007 May; 21(5):965-72. PubMed ID: 17344921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of VH genes mutation status for prognosis of CLL patients.
    Bilous N; Abramenko I; Kryachok I; Bazyka D; Chumak A; Bebeshko V
    Exp Oncol; 2005 Dec; 27(4):325-9. PubMed ID: 16404355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia.
    Catherwood MA; Matthews C; Niblock R; Dobbin E; Morris TC; Alexander HD
    Eur J Haematol; 2006 Apr; 76(4):294-8. PubMed ID: 16519700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
    Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
    Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia.
    ; ; . PubMed ID: 15325098
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.